McKesson (MCK)
(Delayed Data from NYSE)
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
Top Ranked Value Stocks to Buy for July 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, July 26th
McKesson (MCK) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MCK vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
MCK vs. COO: Which Stock Is the Better Value Option?
Is McKesson (MCK) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why the Earnings Surprise Streak Could Continue for McKesson (MCK)
by Zacks Equity Research
McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
McKesson (MCK) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Top-line growth and better-than-expected segmental performance are likely to aid McKesson (MCK) in Q1. However, rise in adjusted operating expenses is likely to be a dampener.
Can Instruments Drive Intuitive Surgical (ISRG) Q2 Earnings?
by Zacks Equity Research
Intuitive Surgical (ISRG) expects its core Instruments and Accessories unit to boost second-quarter 2019 results.
Rite Aid Expands in Northeast With Thrifty Ice Cream Brand
by Zacks Equity Research
Rite Aid (RAD) expands the availability of its Thrifty Ice Cream brand in select stores in Delaware, New York, Maryland, New Jersey and Pennsylvania.
Here's Why You Should Hold on to McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market.
QIAGEN Inks Distribution Deal With Mckesson Medical-Surgical
by Zacks Equity Research
The distribution agreement will enable QIAGEN (QGEN) to expand reach in the healthcare market.
Why Is McKesson (MCK) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News For May 9, 2019
by Zacks Equity Research
Companies In The News Are: COTY,MCK,WEN,QRVO
McKesson (MCK) Q4 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
McKesson's (MCK) Q4 results benefit from higher revenues, gross margin expansion and solid show by U.S. Pharmaceutical and Specialty Solutions.
McKesson (MCK) Tops Q4 Earnings Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 0.82% and -1.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Can Core Business Unit Fuel McKesson (MCK) Q4 Earnings?
by Zacks Equity Research
Anticipated growth across core business unit and solid show by Medical Surgical and European Pharmaceutical Solutions is likely to aid McKesson's (MCK) Q4 earnings. However, rising costs might be a dampener.
McKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why McKesson (MCK) Could Beat Earnings Estimates Again
by Zacks Equity Research
McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Investors Should Retain McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) is well positioned for growth backed by strong business plans and robust surprise trend amid cutthroat competition in the near term.
Top Ranked Value Stocks to Buy for February 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, February 22nd
MCK vs. ALGN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MCK vs. ALGN: Which Stock Is the Better Value Option?
Is McKesson (MCK) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is McKesson Corporation (MCK) a Great Stock for Value Investors?
by Zacks Equity Research
Is McKesson Corporation (MCK) a great pick from the value investor's perspective right now? Read on to know more.
Cardinal Health Strong on Pharmaceutical, Competition Rife
by Zacks Equity Research
Cardinal Health (CAH) is on track to deliver targeted annualized cost savings of $100 million in fiscal 2019.
Here's Why You Should Invest in McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson's (MCK) solid prospects in the pharmaceutical and medical supplies distribution market look promising.
MCK vs. ALGN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MCK vs. ALGN: Which Stock Is the Better Value Option?